{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:04:36Z","timestamp":1780445076396,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.thromres.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T17:46:34Z","timestamp":1615225594000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry"],"prefix":"10.1016","volume":"202","author":[{"given":"Luise","family":"Tittl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Marten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Naue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9921","key":"10.1016\/j.thromres.2021.03.004_bb0005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.thromres.2021.03.004_bb0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/2047487315571890","article-title":"European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care","volume":"23","author":"Hobbs","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.thromres.2021.03.004_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.thromres.2021.03.004_bb0020","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.thromres.2021.03.004_bb0025","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest."},{"issue":"2","key":"10.1016\/j.thromres.2021.03.004_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation."},{"issue":"7","key":"10.1016\/j.thromres.2021.03.004_bb0035","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Laliberte","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.thromres.2021.03.004_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","article-title":"Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban","volume":"38","author":"Tamayo","year":"2015","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.thromres.2021.03.004_bb0045","doi-asserted-by":"crossref","first-page":"h1857","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study","volume":"350","author":"Abraham","year":"2015","journal-title":"Bmj."},{"issue":"14","key":"10.1016\/j.thromres.2021.03.004_bb0050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur. Heart J."},{"issue":"38","key":"10.1016\/j.thromres.2021.03.004_bb0055","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.thromres.2021.03.004_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ehf2.12365","article-title":"Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure","volume":"6","author":"Martinez","year":"2019","journal-title":"ESC Heart Fail."},{"issue":"2","key":"10.1016\/j.thromres.2021.03.004_bb0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/STROKEAHA.119.025554","article-title":"Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin","volume":"51","author":"Alberts","year":"2020","journal-title":"Stroke."},{"issue":"12","key":"10.1016\/j.thromres.2021.03.004_bb0070","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2021.03.004_bb0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2021.03.004_bb0080","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2021.03.004_bb0085","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2021.03.004_bb0090","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1160\/TH14-11-0954","article-title":"Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry","volume":"113","author":"Beyer-Westendorf","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2021.03.004_bb0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11239-017-1519-8","article-title":"Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry","volume":"44","author":"Helmert","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"5","key":"10.1016\/j.thromres.2021.03.004_bb0100","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1160\/TH15-10-0840","article-title":"Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry","volume":"115","author":"Hecker","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"28","key":"10.1016\/j.thromres.2021.03.004_bb0105","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","article-title":"Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry","volume":"35","author":"Beyer-Westendorf","year":"2014","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.thromres.2021.03.004_bb0110","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12391","article-title":"Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care\u2014results from the Dresden NOAC registry","volume":"78","author":"Beyer-Westendorf","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.thromres.2021.03.004_bb0115","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2021.03.004_bb0120","doi-asserted-by":"crossref","unstructured":"Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015;113(6).","DOI":"10.1160\/TH14-11-0954"},{"key":"10.1016\/j.thromres.2021.03.004_bb0125","doi-asserted-by":"crossref","unstructured":"Michalski F, Tittl L, Werth S, Hansel U, Pannach S, Sahin K, et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost. 2015;114(4).","DOI":"10.1160\/TH15-02-0116"},{"issue":"4","key":"10.1016\/j.thromres.2021.03.004_bb0130","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","article-title":"Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry","volume":"17","author":"Beyer-Westendorf","year":"2015","journal-title":"Europace."},{"key":"10.1016\/j.thromres.2021.03.004_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2020.03.021","article-title":"Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY","volume":"190","author":"Beyer-Westendorf","year":"2020","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2021.03.004_bb0140","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2021.03.004_bb0145","series-title":"Gobelt M, et al","author":"Beyer-Westendorf","year":"2015"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:44:50Z","timestamp":1758735890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":29,"alternative-id":["S0049384821000955"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.03.004","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}